Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2023 Results of subgroup analysis (n= 729 from studies NCT03075735, NCT02922218, NCT02362620, and NCT02787837) assessing Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer patients receiving first line treatment stratified by BRCA status presented at the 59th Annual Meeting of the American Society of Clinical Oncology
23 Jan 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
01 Feb 2019 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com